University of Cambridge

A new "pill-on-a-string" capsule sponge test successfully identified 54% of Barrett's esophagus patients as low-risk, potentially eliminating the need for invasive endoscopy surveillance in these cases.

Mary Catchpole, 19, becomes the first European patient to receive leniolisib (Joenja), a newly approved targeted treatment for activated PI3-kinase delta syndrome (APDS), a rare inherited immune disorder.

Spanish National Cancer Research Centre (CNIO) scientists have developed a genomic test that predicts which patients will not respond to three common chemotherapy types, potentially sparing 20-50% of cancer patients from ineffective treatment and severe side effects.

University of Cambridge researchers used GPT-4 to identify drug combinations that could treat cancer, finding that three of 12 AI-suggested combinations outperformed current breast cancer drugs in laboratory tests.

Researchers at the University of Melbourne have developed a proteomic blood test that can analyze thousands of proteins to diagnose rare genetic diseases in children within three days, requiring only 1ml of blood from infants.

Cambridge researchers have developed a promising combination therapy using venetoclax and inobrodib that effectively targets B-cell acute lymphoblastic leukemia (B-ALL), potentially reducing the need for toxic chemotherapy.

A groundbreaking clinical trial led by Addenbrooke's Hospital demonstrates 100% three-year survival rate for patients with BRCA-mutated breast cancer when treated with olaparib plus chemotherapy before surgery.

Young breast cancer patients with BRCA mutations experienced a 35% lower risk of death and 42% lower risk of cancer recurrence after preventive breast removal surgery, according to research presented at the San Antonio Breast Cancer Symposium.

Recent evidence reviews indicate that controlling infections through vaccines, antibiotics, and antivirals may significantly reduce dementia risk, supporting theories linking infectious causes to common dementias.

Cambridge researchers discover that metformin, a widely prescribed diabetes medication, may help prevent acute myeloid leukemia (AML) in high-risk individuals by targeting mutations in the DNMT3A gene.